AUG 27·SEC EDGARLow
Gary M. Huff purchased $50K of BMRA
Gary M. Huff purchased 31,250 shares of BIOMERICA INC (BMRA) at $1.60 on 2026-08-20.
StockNASDAQ · US · USDHealthcare · Medical Devices
$BMRA
BIOMERICA INC
Price · $BMRAvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 0
- Neutral
- 1
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- $158K 5 txs
- Sells
- — 0 txs
Gary M. Huff1× · $50K
10b5-1 share of filings0%
Top stories · $BMRAMore →
AUG 27·SEC EDGAR
MOATAZEDI DAVID purchased $16K of BMRA
MOATAZEDI DAVID purchased 10,000 shares of BIOMERICA INC (BMRA) at $1.60 on 2026-08-26.
AUG 27·SEC EDGAR
Chin Eric purchased $10K of BMRA
Chin Eric purchased 6,250 shares of BIOMERICA INC (BMRA) at $1.60 on 2026-08-26.
BMRA sentiment & insider activity
Over the past 7 days, alphai's AI scored 1 news story mentioning BMRA (BIOMERICA INC). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent BMRA coverage spans insider activity, financial news and corporate actions.
In the last 30 days, BMRA insiders filed 5 SEC Form 4 transactions — 5 purchases ($158K) and no sales. The most active reporter was Gary M. Huff with 1 filing.
What's driving BMRA
Small insider purchase by a director may signal confidence but the amount is modest.
Small insider purchase by a director; unlikely to move the stock materially.
Minor insider purchase by a director; limited price impact.
Small insider purchase may signal confidence but size is modest.
Insider purchase by the CEO may signal confidence but the amount is modest relative to holdings.
alphai scores every news story that mentions BMRA with an AI model for sentiment and relevance, and aggregates insider trades from BIOMERICA INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $BMRA
Score
Gary M. Huff purchased $50K of BMRA
Gary M. Huff purchased 31,250 shares of BIOMERICA INC (BMRA) at $1.60 on 2026-08-20.
1 min readMOATAZEDI DAVID purchased $16K of BMRA
MOATAZEDI DAVID purchased 10,000 shares of BIOMERICA INC (BMRA) at $1.60 on 2026-08-26.
1 min readChin Eric purchased $10K of BMRA
Chin Eric purchased 6,250 shares of BIOMERICA INC (BMRA) at $1.60 on 2026-08-26.
1 min readBARBIERI ALLEN purchased $32K of BMRA
BARBIERI ALLEN (Executive Vice Chairman) purchased 20,000 shares of BIOMERICA INC (BMRA) at $1.60 on 2026-08-26.
1 min readIrani Zackary S. purchased $50K of BMRA
Irani Zackary S. (Chief Executive Officer) purchased 31,250 shares of BIOMERICA INC (BMRA) at $1.60 on 2026-08-26.
1 min readBIOMERICA INC (BMRA): Entry into a Material Definitive Agreement
BIOMERICA INC (BMRA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Private Placement On August 20, 2026, Biomerica, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and individual investors identif
2 min read
Biomerica Wins $1.75M Contract to Develop Diagnostic Tests
Biomerica Inc. said it was selected for a $1.75 million master services agreement with an undisclosed life sciences company to develop in vitro diagnostic assays. The three-year work will be performed at Biomerica’s Irvine facility, according to the company. Biomerica said the initial fees provide near-term revenue visibility. Shares fell 2.2% to $2.40.
3 min read
Up to 5 million Canadians have IBS; Biomerica brings inFoods north
Biomerica (Nasdaq: BMRA) has launched its inFoods® IBS platform in Canada through partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs. This marks Biomerica's first commercial entry into Canada, aiming to address the estimated 18% prevalence of IBS (up to 5 million Canadians) with a clinically validated, non-pharmaceutical, diagnostic-guided therapy. The initiative seeks to fill a significant unmet need in a market largely focused on pharmaceutical symptom management.
2 min read
BMRA PE Ratio & Valuation, Is BMRA Overvalued
Biomerica Inc (BMRA) is currently considered undervalued based on its forward P/S ratio of 0.28, significantly lower than its five-year average of 12.51. The fair price for BMRA is estimated between 3097.35 to 3125.16, making its current price of 2.19 USD appear to be undervalued by 99.93%. Despite a P/S ratio that is -99.98% above the industry average, its revenue growth of -26.04% suggests this premium may be unsustainable.
3 min read
Biomerica's inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS - Biomerica (NASDAQ:BMRA)
IRVINE, Calif., Nov. 25, 2025 ( GLOBE NEWSWIRE ) -- Biomerica, Inc. ( NASDAQ:BMRA ) , a global provider of advanced medical diagnostic solutions, is proud to announce that its inFoods® IBS diagnostic-guided therapy product is being featured in the Fall 2025 issue of Biotherapeutics Quarterly, a ...
2 min read